A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...
The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhibitors now in development—with their unique safety and activity profiles—suggest the...
As reported in The New England Journal of Medicine by Geyer et al, interim analysis of overall survival in the phase III KATHERINE trial showed a significant benefit of ado-trastuzumab emtansine (T-DM1) vs trastuzumab in patients with residual invasive HER2-positive breast cancer after neoadjuvant...
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed a significant benefit with the addition of pertuzumab retreatment to trastuzumab plus physician’s choice of chemotherapy (PTC) in patients with...
Investigators have found that although fewer patients may be diagnosed with and dying from cancer in Appalachia, cancer incidence and mortality rates remain substantially higher compared with elsewhere in the United States, according to a recent study published by Burus et al in the Journal of the...
A novel artificial intelligence (AI) tool uncovered an effective treatment for a patient with idiopathic multicentric Castleman’s disease, according to a recent study published by Mumau et al in The New England Journal of Medicine. Background Idiopathic multicentric Castleman’s disease is a rare...
Patients with stage III or IV clear cell renal cell carcinoma may have achieved a successful anticancer immune response following initiation of a novel personalized cancer vaccine, according to a recent study published by Braun et al in Nature. Background The standard treatment for stage III or IV...
Researchers have found that inhibiting the S6K2 gene could be an effective strategy for managing treatment-resistant melanoma, according to a recent study published by Lipchick et al in Science Translational Medicine. Background Cases of melanoma—the deadliest type of skin cancer—are currently...
On January 21, the U.S. Food and Drug Administration (FDA) approved treosulfan (Grafapex), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia ...
A retrospective study provides new evidence that thyroid cancer continues to be overdiagnosed and that aggressive screening and treatment of thyroid cancer has not led to higher survival rates. The research was published by Chen et al in The Lancet Diabetes & Endocrinology. “Many studies have...
In a retrospective cohort study from Memorial Sloan Kettering Cancer Center, which was reported in JAMA Network Open, Ferraro et al found that patients with ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer and central nervous system (CNS) metastases only vs concomitant extracranial...
First-line treatment with the Bruton’s tyrosine kinase inhibitor zanubrutinib plus the anti-CD20 monoclonal antibody obinutuzumab and the BCL2 inhibitor venetoclax appeared to be safe and active in previously untreated patients with TP53-mutated mantle cell lymphoma, based on the results of the...
High-risk patients with clonal cytopenia of undetermined significance have very similar characteristics and outcomes as patients with lower-risk myelodysplastic syndrome (MDS), which can be informative with regard to prognosis, management, and clinical trial eligibility, said Zhuoer (Zoey) Xie, MD, ...
Researchers have found no evidence that chimeric antigen receptor (CAR) T-cell therapy caused secondary cancers in the modified T cells, according to a recent study published by Jadlowsky et al in Nature Medicine. Background CAR T-cell therapy is a personalized type of immunotherapy that employs...
The risk of developing more serious long-term urinary and bowel health issues may be higher in men undergoing radiation therapy for prostate cancer who experience side effects early in treatment, according to a recent study published by Nikitas et al in The Lancet Oncology. The findings highlighted ...
In a phase Ib study reported in the Journal of Clinical Oncology, Wilky et al found that the combination of botensilimab (Fc-enhanced anti–CTLA-4 antibody) and balstilimab (anti–PD-1 antibody) yielded activity in patients with relapsed or refractory metastatic sarcomas. Study Details In the trial,...
As reported in the Journal of Clinical Oncology by Mascarenhas et al, follow-up of a cohort of pediatric patients with TRK fusion sarcomas and related mesenchymal tumors treated with larotrectinib showed that discontinuation of treatment—with resumption for progressive disease—was associated with...
The results from the phase III FIRE-4 randomized clinical trial show that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type–mutated metastatic colorectal cancer. The findings confirm the high clinical relevance of liquid biopsy performed at baseline before the start of...
Although artificial intelligence (AI)-assisted radiotherapy may help physicians make more informed decisions when treating patients with cancer, there may be challenges in how physicians work with the technology, according to a recent study published by Niraula et al in Nature Communications. Study ...
Researchers have provided novel insights into the effects of radiation on the immune cells surrounding breast cancer tumors, according to a recent study published by Yoneyama et al in the International Journal of Radiation Oncology • Biology • Physics. The findings revealed that the relationship...
In a study reported in a research letter in JAMA Oncology, Abboud et al found that the incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased in many organ sites during recent years in the United States. Study Details In the study, age-adjusted GEP-NETs incidence rates...
In a retrospective cohort study reported in JAMA Oncology, Stoop et al found that use of adjuvant modified leucovorin, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) and other multiagent chemotherapy regimens improved overall survival vs no adjuvant chemotherapy in patients with localized...
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...
The U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone receptor (HR)-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with fam-trastuzumab...
Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...
Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research. Study Methods and Results Researchers developed ...
The incidence of advanced prostate cancer rose and the mortality rate plateaued in most regions across the state of California following the decision to cease routinely screening all men for the disease, according to a recent study published by Van Blarigan et al in JAMA Network Open. The findings...
In a Japanese noninferiority phase III trial (EMERALD) reported in the Journal of Clinical Oncology, Yamashita et al found that the addition of eribulin to trastuzumab/pertuzumab (HP) was noninferior in progression-free survival vs the addition of a taxane to HP in the first-line treatment of...
In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation was noninferior to surgical resection in terms of overall survival in patients with small resectable colorectal liver metastases. Study Details In...
In a Singaporean phase II trial reported in The Lancet Oncology, Chong et al found that the addition of bevacizumab to pembrolizumab improved objective response rate in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma. Study Details In the open-label trial, 48...
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
Worldwide, cancer chemotherapy is linked to chronic painful neuropathy for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence published by D’Souza et al in Regional Anesthesia & Pain Medicine. Notwithstanding wide regional...
Misdiagnosing cancer symptoms as normal pregnancy-related changes among pregnant individuals could lead to delays in treatment, according to a recent study published by Marcu et al in the British Journal of General Practice. Study Methods and Results In the study, researchers recruited 20 women...
Fallopian tube removal performed during other abdominal surgeries could reduce the risk of ovarian cancer incidence among women who have already completed their families, according to a recent study published by Kather et al in PLOS Medicine. Background Ovarian cancer is the third most common...
Researchers have uncovered new heredity genes that may contribute to an increased risk of developing high-grade serous ovarian cancer, according to a recent study published by Subramanian et al in npj Genomic Medicine. Background High-grade serous ovarian cancer is one of the most prevalent and...
Researchers have found that asymptomatic brain metastases may be more common in patients with stage IV breast cancer than previously understood, according to a recent study published by Ahmed et al in Neuro-Oncology. The findings suggest that physicians may need to reconsider current screening...
In the phase III EMERALD-1 trial reported in The Lancet, Sangro et al found that transarterial chemoembolization (TACE) with durvalumab/bevacizumab improved progression-free survival vs placebo in patients with unresectable hepatocellular carcinoma (HCC) amenable to embolization. Study Details In...
A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates. CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...
In a phase Ib-II study (MORPHEUS-Liver) reported in The Lancet Oncology, Finn et al found that the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab/bevacizumab improved objective response rate in patients with unresectable, locally advanced, or metastatic hepatocellular...
A novel system using standing surface acoustic waves may effectively and precisely separate circulating tumor cells from red blood cells, according to a novel study published by Kouhkord and Naserifar in the Physics of Fluids. Background Cancer accounted for nearly 10 million deaths in 2020—nearly...
Treatment with the oncolytic virus talimogene laherparepvec may be effective in patients with basal cell carcinoma, according to a novel study published by Ressler et al in Nature Cancer. Background Although basal cell carcinoma—which typically occurs in chronically sun-exposed areas such as the...
Oral fecal microbiota transplantation may be a feasible and safe option to prevent graft-vs-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant (ASCT), according to a recent report published by Reddi et al in Nature Communications. The findings built on ...
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...
In a German phase III trial (ESOPEC) reported in The New England Journal of Medicine, Hoeppner et al found that perioperative chemotherapy with fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) improved overall survival vs preoperative chemoradiotherapy in patients undergoing surgery for locally ...
This is Part 3 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the management of...
This is Part 2 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the management of moderate...
This is Part 1 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the first-line treatment of...
The randomized, double-blind, multicenter, placebo-controlled ALASCCA Trial screened 3,508 patients across 33 hospitals in Sweden, Denmark, Finland, and Norway for eligibility. They either had stage II or III colon cancer or stage I, II, or III rectal cancer. Ultimately, 626 patients continued on...
The U.S. Food and Drug Administration (FDA) has provided a safety announcement to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil related to the risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Background Fluoropyrimidines are a...
Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, reported on findings from the FRESCO-2 study, focusing on overall survival with fruquintinib vs placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer (Abstract 171). Abstract 171, a...